{
  "docId": "019de070-3a76-76eb-bdcd-70a194f2629a",
  "docSlug": "3b5651eafaa236908b5aaeea5fdc2dcc",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 28,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a 3-column layout to map programs to their respective 2020 momentum/milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3a76-76eb-bdcd-70a194f2629a/3",
  "deckHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a",
  "deckJsonHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a.json",
  "deckAnchorHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.27,
        "x": 0.36,
        "y": 0.67
      },
      "kind": "list",
      "text": "CTA approved by MHRA\nPh 1/2 trial initiated\nPh 1/2 first patient dosed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6b2fa47-2113-4543-aa89-d55d3b11d38d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.27,
        "x": 0.07,
        "y": 0.67
      },
      "kind": "list",
      "text": "1-year OLE data\nPivotal Ph 3 enrollment completion\nTopline Ph 3 data (1Q21)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b70e80b5-bfc2-4c79-b58b-b6fd3a6a3b1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.27,
        "x": 0.65,
        "y": 0.67
      },
      "kind": "metric",
      "text": "$138m financing to support clinical and platform programs; runway through 2022",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7de6969f-465b-439b-809a-0b00fd437c61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.27,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Pegzilarginase in Arginase 1 Deficiency\nEnhanced human arginase that enzymatically lowers levels of the arginine\nPEACE – pivotal Phase 3 trial enrolling",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "635ee655-ce59-4cbd-8a88-b7249762a6c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.27,
        "x": 0.65,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Enzyme Therapeutics Platform\nRare metabolic-disease, monogenic focus\nMost advanced program in Cystinuria",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74f70ad9-1e82-4912-99cf-87047eaa2f76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.27,
        "x": 0.36,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "ACN00177 in Homocystinuria\nNovel recombinant human enzyme that degrades the amino acid homocysteine\nPhase 1/2 trial ready for initiation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88e4f4e6-10a9-4aaa-89c9-d9456259222f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.585
      },
      "kind": "title",
      "text": "2020 Momentum",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52ccbca9-9936-4168-a148-3b58ce8a7f11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Advancing Programs Set Stage for Transformative 2021",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fafec91d-519b-40d4-90c1-4a66375cea2f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Three-Act Structure",
      "slug": "three-act-structure",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e87c2a69-6e2b-4ee1-82ee-3eb24219dd46",
      "evidence": "The slide presents a clear progression from the current state to future goals, aligning with a three-act structure.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}